Healios K.K.
N/A
Our company has been adopted as a support research project under AMED for industrializing regenerative medicine and gene therapy, and is advancing the development of a commercial production process for eNK® cells for the treatment of intractable cancers. The direct impact on future performance is currently undetermined.
Key Figures
- Maximum Subsidy Amount: Approximately 240 million yen
- Annual Subsidy Amount: 79,933 thousand yen (including indirect expenses)
- Research Project Name: AKT-01/HLCN061 for Malignant Mesothelioma
AI要約
Background and Purpose of Research and Development
Our company is conducting research and development on the commercial manufacturing of gene-engineered iPS cell-derived NK cells (eNK® cells) for the treatment of intractable cancers, supported by AMED, aiming to establish a manufacturing process targeting malignant mesothelioma. This aims to promote the industrialization of regenerative medicine and gene therapy, supporting the establishment of quality and manufacturing methods at the preclinical stage.
Future Outlook and Impact
At present, the direct impact on our consolidated performance for the fiscal year ending December 2026 remains unknown. As research progresses and clinical trials commence, important information will be disclosed promptly once clarified. Research and development are ongoing, with aims for future commercialization and business development.
G-Helios
Company overview · Stock price · Financial data · All IR
